{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '4.0 STUDY DESIGN', '4.1', 'Overall Design', 'This is an open-label, single arm, multiple dose study to assess the clinical efficacy, as well as', 'the safety, tolerability, and PK of multiple doses of ANB019 in subjects with GPP.', 'The screening period will be up to 42 days (6 weeks) prior to administration of study drug on', 'Day 1. Written informed consent will be obtained from each subject prior to initiating any study', 'related procedures. All screening procedures will be conducted in accordance with the Schedule', 'of Activities (see Section 1.3).', 'On Day 1, subjects who meet the entry criteria will receive a 750 mg IV dose of ANB019 in an', 'open-label manner followed by 3 doses of 100 mg SC administered on Days 29, 57, and 85.', 'Subjects will leave the study center after completion of the 5 hours postdose assessments', 'following IV administration and the 3 hours postdose assessments after the first and second SC', \"injections and with the Investigator's approval. Subjects with any ongoing AEs or SAEs at the\", 'time of scheduled discharge from the study center should remain at the study center until the', 'Investigator has determined that these events have resolved or are deemed as not clinically', 'significant.', 'After completing Day 1 assessments, the subjects will return to the study center for follow-up', 'visits on Days 3, 8, weekly from Day 8 to Day 29, and every other week up to Day 85, and', 'monthly for 12 weeks to monitor changes in disease activity, safety, and tolerability. In addition,', 'subjects will be contacted via phone by study staff to assess for safety (eg, AEs and changes in', 'concomitant medications) on Days 36, 50, 64, and 78.', 'Subjects who are nonresponders will be early terminated 4 weeks after the 750 mg IV dose', 'administration. A nonresponder is defined as:', '\"No change\" on CGI: 0 points change in JDA total score and not meeting \"other criteria\" for', 'minimally improved.', '\"Worsened\" based on CGI: >1 -point increase in JDA total score.', 'Disease activity (response to study treatment) will be evaluated using the CGI scale according to', 'the modified JDA severity index, change in total BSA as measured by modified JDA index', 'affected by GPP, systemic manifestations and laboratory findings as per modified JDA severity', 'index, GPPPGA scale, and PASI score (if PP is present). In addition, change in serum cytokines', '(including but not limited to IL-8) will be recorded. Quality of life (QoL) will be assessed using', 'the DLQI.', 'Serum samples for PK and immunogenicity will be collected before the administration of', 'ANB019 and at the other time points specified in the Schedule of Activities (see Section 1.3).', 'Refer to Table 2 for additional information on sample collection and time points. All subjects', '29 October 2019', '24']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'enrolled in the study will be asked to participate in the skin biopsy and/or genetic analysis;', 'however, participation is optional and subjects will be asked to give specific consent for these', 'assessments.', 'Safety assessments including AE/SAE monitoring, vital signs measurements, physical', 'examination, ECGs, laboratory measurements, and urine assessments will be performed during', 'the study.', 'The EOS visit will be on Day 169 and all subjects will return to the study center for the EOS', 'procedures (see Section 1.3).', '4.2', 'Scientific Rationale for Study Design', 'Currently there are no approved treatment modalities for use in subjects with GPP, and there is', 'little evidence-based information to guide the management of this severe, life-threatening type of', 'psoriasis.', 'In this context, the development of agents with new mechanisms of action is considered', 'important for future clinical practice. This open-label single arm multiple dose study may', 'provide evidence-based information about the clinical effect of this novel treatment.', '4.3', 'Justification for Dose', 'ANB019 will be administered as a single IV dose of 750 mg followed by 3 doses of 100 mg SC', 'administered on Days 29, 57, and 85.', 'The doses selected for this study have demonstrated favorable safety profile and prolonged', 'pharmacodynamic activity in a Phase I study (ANB019-001). A loading dose of 750 mg IV will', 'be administered on Day 1 to enable steady state concentration to be reached faster at initiation of', 'the ANB019 100 mg SC dose. The 12-week treatment duration is expected to provide adequate', 'time to assess the safety and efficacy of ANB019 in subjects with GPP.', '4.4', 'End of Study Definition', 'A subject is considered to have completed the study if they have completed all protocol specified', 'visits including the last visit on Day 169 (see Section 1.3).', 'The EOS is defined as the date of the last visit of the last subject in the study.', '4.5', 'Study Stopping Criteria', '4.5.1', 'Stopping Criteria for Individual Subjects', 'Dosing for any individual subject will be stopped if the subject experiences a SAE or a clinically', 'significant possibly drug related AE, which in the opinion of the study physician, Investigator, or', \"Sponsor's medical representative, warrants discontinuation of the study for that subject's\", 'wellbeing. Details on subject withdrawal are presented in Section 7.0.', '29 October 2019', '25']\n\n###\n\n", "completion": "END"}